News

Pharmabiz1h
Kairos Pharma reports positive results from phase 2 trial of ENV-105 in advanced prostate cancer
Kairos Pharma reports positive results from phase 2 trial of ENV-105 in advanced prostate cancer: Los Angeles Thursday, July 17, 2025, 15:00 Hrs [IST] Kairos Pharma, Ltd., a clini ...
Investornewsbreaks Kairos Pharma Ltd. (NYSE American: KAPA) To Present At H.C. Wainwright Global Investment Conference
Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th ...
CURE19h
Carotuximab Combo Proves Safe for Advanced Prostate Cancer
Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on ...
PipelineReview.com21h
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
LOS ANGELES, CA, USA I July 15 2025 I Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer ...
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright ...